It is a question that needs clinical trials for answers
A: Each batch is manufactured following GMP certification, involving rigorous quality control checks, sterile production environments, and proper documentation to maintain efficacy and safety
Since the accumulation of uremic toxins in CKD patients engenders various neurological complications, treatments that target the significant reduction of these metabolites not only significantly delay CKD progression but also greatly improve cognitive function in these patients (Faucher et al., 2023)
The Phase I trial of the novel HDAC inhibitor Bisthianostat (BIS, oral tablets, starting dose of 100 mg, escalated to 200/400 mg, administered twice weekly) demonstrated good safety as a monotherapy, with no Grade 3/4 non-hematologic toxicities
J Leukoc Biol 76(1):169175 Ghezzi P, Jaquet V, Marcucci F, Schmidt HH (2017) The oxidative stress theory of disease: levels of evidence and epistemological aspects
At Refine by Tulsi, we match NAD+ therapy to your lifestyle, not a template
